Abstract
The recent development of biological therapy has revolutionized care for patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and other diseases. Treatment with biologics can provide significant symptomatic and functional improvement. However, these agents have been associated with risks of compromised healing, such as infection, owing to their systemic blockade of mediators to the normal inflammatory responses required for tissue healing and immune surveillance. Given these potential risks and benefits, the question of how best to manage biologic therapy before planned surgery is an important consideration for practitioners. In an attempt to answer this question, we performed a review of the literature on this topic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
